Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 212932, held by Amneal. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 212932 (Ephedrine Sulfate), held by Amneal, was first approved by FDA on Oct 23, 2019, with 2 approved supplements and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Mar 31, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 31, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 23, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters